Personalized 3D Bioprinted Colorectal Cancer Microenvironment Model
Official title: Construction of a 3D Multicellular Bioprinted Human Colorectal Cancer Immune-Stromal Microenvironment Model and Its Clinical Translational Research
Run by Peking Union Medical College Hospital · NCT07919418 · Data updated 2026-11-12
This study tests patient-derived, 3D-bioprinted cancer models that include tumor, fibroblast, and immune cells to see if they can better predict how colorectal cancer will respond to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 60 (estimated) |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Ningbo, Zhejiang) |
| Status | Recruiting |
| Started | May 24, 2025 |
| Main results expected | November 1, 2026 |
| Study ends | December 31, 2028 |
| Registry record updated | November 5, 2026 |
| Trial ID | NCT07919418 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults over 18 with colorectal cancer who have undergone surgery, with or without liver metastases.
✕Probably not a fit
Patients whose tumors do not yield robust model readouts or who cannot provide usable tissue samples may not benefit from the model.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will create patient-specific 3D bioprinted models of colorectal cancer that incorporate cancer cells, cancer-associated fibroblasts, and PBMC immune cells. These models will be used to screen therapies and predict prognosis, with integration of multi-omics data to understand why tumors resist chemotherapy and evade immunity. The study leverages surgical samples and combines translational modeling with clinical drug screening to inform personalized treatment decisions. It is observational, focusing on model development and correlative analyses rather than testing a single therapy in patients. The goal is to provide a broadly applicable preclinical platform to advance precision therapy for colorectal cancer.
Why it matters
Potential benefit: If successful, patients could benefit from more accurate predictions of which therapies are likely to work for their tumor.
How similar studies have gone: Prior research supports the use of patient-derived, multi-cellular 3D models to study tumor biology, though applying this approach to routine precision therapy guidance is still emerging.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * More than 18 years old * Diagnosed as colorectal cancer with or without liver metastases before * Pathologically proven colorectal cancer after surgery Exclusion Criteria: * Medical history with other malignancies or serious diseases * Disable to sign the informed consent independently
Where it's running
-
Ningbo Medical Center Lihuili Hospital
Ningbo, Zhejiang, China Recruiting
Study contacts
- Principal investigator: Yilei Mao, MD PHD — Peking Union Medical College Hospital
- Study coordinator: Yilei Mao, MD PHD
- Email: pumch-liver@hotmail.com
- Phone: 8600-010-69156042
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Knife-assisted full-thickness resection for rectal lesions in a multicenter setting
A multicenter study tests knife-assisted full-thickness resection (kFTR) to remove rectal lesions in adults and see how well it works and how safe it is.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Prehabilitation with Resistance, Aerobic, or Both Before Colorectal Surgery
Four pre-surgery exercise options (resistance, aerobic, both, or none) will be tested to see which best reduces complications after colorectal cancer surgery.
-
Liver transplantation for colorectal cancer with liver metastases
This study follows adults with stage IV colorectal cancer whose disease is limited to the liver and who are getting a liver transplant as part of their cancer care to see how they fare over time.
-
LTZ-232: a first-in-human test in advanced colorectal and other solid tumors
A first-in-human study tests LTZ-232, a new therapy for adults with unresectable or metastatic colorectal cancer and other solid tumors that have not responded to standard treatments.
-
SumMET: Targeted radioligand therapy for c-MET–positive solid tumors
This first‑in‑human study tests the safety and potential effectiveness of a radioligand therapy called [225Ac]Ac-FL-261 in adults with advanced or metastatic solid tumors that overexpress c-MET.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.